May 20th OBN BioTuesday - "How to dress for Pharma Acquisition" featuring SVLS and Atlas Venture  

Presentations are only available to member companies (Upgrade)
	Dr Hamish Cameron, Venture Partner, SV Life Sciences Sciences LLP (How to Dress for Pharma Acquisition)

This event is kindly sponsored by MEPC Milton Park

May's BioTuesday addresses two key issues facing biotech and healthcare companies in a climate where pharma acquisition is now a frequent exit, firstly how to position a company for trade sale, and how to attract the investment you need to get to trade sale.

May's BioTuesday features Dr Hamish Cameron, who was CEO of "CAT" following its acquisition by AstraZeneca. "How to Dress for Pharma Acquisition" addresses the one of the key issues facing cash hungry biotechs, looking for pharma trade sale as an exit.  The UK has seen a quickening pace of acquisition activity in the last few years, including the acquisition of Zeneus Pharma (Oxford) by Cephalon, and the acquisition of PowderMed (Oxford) by Pfizer, and there are even rumoured to be bids planned for larger biotech companies.  This BioTuesday seeks to discuss and dissect the steps that a biotech company should take if it is to position itself as an acquisition target for pharmaceutical.

The May BioTuesday will feature another life sciences investment firm, Atlas Venture.    Dr Hakan Goker of Atlas Venture will give the low down on "How to Dress for an Atlas Venture", following an afternoon spent meeting companies through OBN's VC Meeting Brokerage service.

 Add to Outlook Calendar

Confirmed speakers:

Dr. Hamish Cameron, Venture Partner, SV Life Sciences

Dr Hakan Goker, Analyst, Atlas Venture

Biographies
Dr Hamish Cameron joined SVLS in 2008 as a Venture Partner. Before joining SVLS, Dr Cameron was CEO of Cambridge Antibody Technology ("CAT"). Prior to that, he held a series of senior R&D positions at AstraZeneca/Zeneca including Head of the Cardiovascular Therapy Area, Senior Vice-President Medical Research and was a member of the R&D Leadership Team. Dr Cameron started his industry career with Janssen, after working in clinical practice and research in the UK. Hamish was trained as a physician and holds MBBS and BSc (Hons) Pharmacology degrees from the University of London. He is a member of the UK Royal College of Physicians and a Fellow and past Board member of the Faculty of Pharmaceutical Medicine.

More information about SVLS: http://www.svlsa.com/pages/entrepreneurs.htm

Hakan Goker is an Analyst in the life sciences group, and joined Atlas Venture in 2006. Previously, he worked as a Postdoctoral Fellow at the Institute of Cancer Research / Royal Marsden Hospital and the Breakthrough Breast Cancer Centre in the fields of cancer and development. Hakan holds a Bsc (Hons) in Human Genetics from University College London. He obtained a PhD for his work in the area of molecular cytogenetic analysis of testicular germ cell tumours at the University of London's Institute of Cancer Research. Hakan has authored and co-authored publications in leading scientific journals, including Oncogene and the British Journal of Cancer.

More information about Atlas Venture: http://www.atlasventure.com

How to register for the May 2008 BioTuesday:

Contact Rachael Tidbury including the delegate name, job title, corporate email address or phone 01865 594 644 to reserve your place at this event, or register online. From January 1st 2008, OBN's Membership Scheme is "live" and our charging structure is varying slightly: BioTuesdays are free for delegates from biotech and healthcare companies who are Full Members of OBN, free to attend for our Sponsors as well as Academics, while Associate Member companies get one free place and pay £21.50 + VAT for further delegates, and everyone else must pay £42.50 + VAT to attend. If you want to attend but your company is in genuine financial hardship, or if you are a contractor between roles, or another special case do contact us to make your case for a fee waiver. If you want to attend and you are not sure if your company is a member of OBN at the moment, contact Jon Rees to discuss on 01865 594642. Click here for Terms and Conditions

Talks: 18.30 - 19.20pm (20 minutes per speaker plus Q&A)
18.30 Welcome by Dr. Jon Rees, Network Director OBN
18.35 Dr. Hamish Cameron, Venture Partner, SV Life Sciences
19.55 Dr. Hakan Goker, Analyst, Atlas Venture

Networking Reception with Buffet and Wine: 8.00pm - 9.30pm

 Location:

97 Milton Park, Abingdon, Oxfordshire OX14 4RR
There is sufficient free car parking at the venue, and Didcot railway station is 5 minutes' drive away, totalling about 45 minutes travel time from London Paddington.  To locate building 97 within Milton Park, take a look at the Milton Park Bioscience Logomap

OBN Meeting Brokerage with SV Life Sciences or Atlas Venture

If you are interested in a one-to-one meeting with SVLS or Atlas on May 20th 2008, during the daytime before the May BioTuesday, to pitch for investment in your biotechnology, medical device and healthcare technology business please read their investment criteria, and if there's a fit - forward a non-confidential business plan to OBN jon.rees@oxfordshirebioscience.net specifying which company you are interested in meeting (or both).

You should be available to attend a 30 minute - 2 hour meeting between on May 20th at Milton Park. You will be informed if you are selected by SVLS. If you hear nothing before May 14th you have not been selected for the May 20th meeting slots. If you are unavailable at that time, we may be able to help arrange a one-to-one meeting on another occasion. More information on SVLS and Atlas Venture investment criteria will be available here closer to the event.

Who should attend?

OBN prides itself on being an Open Network, which welcomes professionals warmly - you don't have to be a member to attend, once you have attended two or three meetings please give consideration to joining as a member - you'll probably save money and time dealing with invoices! Delegates travel from all over the UK to attend OBN's networking evenings, including about 20% from London and Cambridge, 50% from Oxfordshire, and a further 30% from the South-East of the UK.  Networkers tend to be executives and senior managers from a business background from within the industry, and its support services, and entrepreneurial academics, MBA students and PhDs are welcome to attend. Participants attend from therapeutic and biotechnology, diagnostics, medical device technology, healthcare and investment sectors.  Participation is not open to members of the general public: you may be asked to answer a few questions to confirm your identity before being enrolled.  We've also compiled some demographic statistics in our brochure About OBN (PDF format) for detail.

About SV Life Sciences

SV Life Sciences is a venture capital adviser and manager that provides finance to businesses at all stages of development and across the human life sciences sector. These sectors range from biotechnology & pharmaceuticals to medical devices & instruments, to healthcare information technology and services. SV Life Sciences currently advises or manages five funds with capital commitments of approximately $1.6 billion which primarily invest amounts of between $1m and $20m in North America and Europe. Notable recent investments include newcomer Vantia Therapeutics, which acquired an early-stage pipeline from Ferring in March 2008.

About Atlas Venture

Atlas Venture invests primarily in early stage technology and life sciences businesses in the U.S. and Europe. Our life sciences team has been an early investor in over 95 biotechnology companies. Atlas actively manages 32 of these companies today while making new investments in drug discovery and biotechnology. More than 20 of their investments have gone public, with an aggregate market capitalization in excess of $8 billion. Atlas's investments include Renovo, the anti-scarring therapeutic company which recently released positive results on Juvista.

Atlas typically invests in:

• Product companies with clinical candidates or molecules in the clinic;
• Drug discovery companies with best in class technologies to accelerate and improve lead generation and optimization, make new targets accessible to drug intervention, shorten the path to the clinic or change the overall cost equation;
• Select medical device, technology and tool companies.

How to get to BioTuesdays at Milton Park

Milton Park is a five minute drive from Didcot Parkway rail station, which is only 35 minutes from London Paddington by train.

There are regular buses from Didcot Parkway to Milton Park every 10 minutes until 18.30

There are taxi rank services available from Didcot Parkway, and the following are contact details of reputable private hire cabs in the area:
- Abbey Executive Travel - (01235) 820808
- Busby's Taxis - (01235) 555735
- Harold's Taxis - (01235) 512345
- Toot's Taxis - (01235) 555599
- LadyCars (Ladies & Children) - (07779) 760391
- Pryor's Taxis - (01235) 812345
- Star Cars of Didcot - (07702) 800999

Returning to London after BioTuesday

There are trains running back from nearby Didcot Parkway railway station (~3 miles from Milton Park) to London Paddington every 20-40 minutes on weekdays with a journey duration between 54 and 64 minutes. Avoid the occasional stopping services which take twice as long. The following times are intended as a guide only, please check the National Rail website before you travel: 21:37, 21:51, 22:07 (1 change), 22:47, 23:18, the last train currently being 00:39

Click here for a map of Milton Park of the immediate area around the venue, to help you find 97. You can also ask for directions at the security lodge.
You can also find travel directions on the Milton Park website.